Abstract: Most existing researches treated pharmaceutical product development process as a sort of "black box." This paper, however, will focus on the product development process to explore the organizational capabilities and effective development patterns. Interviews and statistical analyses with leading companies in Japanese pharmaceutical industry indicated that "go or no-go decision" is the significant organizational capability, in fact differing among companies, which effects performances in pharmaceutical product development process. This organizational capability is accumulated through experiences in pharmaceutical product development projects.
Introduction
What are the organizational capabilities that influence performances in pharmaceutical product development? In the last decade, studies in fields of innovation management and technology management focused on organizational capabilities and the origin of competitive advantage in product development process of automobile, main frame computers, and software industries (Clark & Fujimoto, 1991 : Cusumano & Selby, 1995 Eisenhardt & Tabrizi, 1995; Iansiti, 1998) . However, in pharmaceutical industry studies, product development process has been deemed rather as a "black box." There were company level studies on management and organizational capabilities, nevertheless, few investigated management and
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organizational capabilities of product development process (Bierly & Chakrabarti, 1996; Gambardella, 1995; Graves & Langowitz, 1993; Henderson & Cockburn, 1994; Omta, Bouter, & van Engelen, 1994) .
In pharmaceutical product development, likelihood of success is extremely low; one in few thousands to 10 thousand (JPMA, 2002 Among these, "decision of go or no-go" was the most frequently named factor, which nearly all interviewees regarded significant. 
The Decision Pattern of Japanese Pharmaceutical Companies
We conducted statistical analysis using data of 10 major Japanese pharmaceutical companies; namely, Consequently, what reflects capabilities of pharmaceutical manufacturers is assumably not "success rate in clinical development," but "decision pattern of go or no-go." In an interview of major Japanese pharmaceutical companies, most named Takeda Chemical Industries, Ltd. as having great clinical development capability (Kuwashima, 1999) .
However, we can see in our analysis that Takeda is sixth among 10 in clinical development stage success rate (Table 2) . On the contrary, when we look at survival distribution function, that is decision pattern of go or no-go, Takeda draws an almost ideal pattern (See Figure 1) . Figure 1 compares the 
Conclusion
We focused on product development process, which have been regarded as a "black box" in pharmaceutical industry in order to examine effective product development pattern and organizational capabilities on the firm's performance. 
